FDA 3.0 Modernization Act Compliant

Predict Toxicity.
Protect Patients.

Human organ-on-chip toxicity screening that outperforms animal models. Detect hepatotoxicity, cardiotoxicity, nephrotoxicity, and neurotoxicity before clinical trials begin.

90%

Drug Failures from Toxicity

87%

DILI Prediction Accuracy

$2B+

Cost of Late-Stage Failures

10x

Faster Than Animal Studies

Multi-Organ Toxicity Screening

Comprehensive toxicology assessment across all major organ systems on a single integrated platform.

Cardiotoxicity

hERG channel screening, QT prolongation risk, arrhythmia prediction, and contractility assessment using human cardiomyocytes.

Hepatotoxicity (DILI)

Drug-induced liver injury detection with bile canaliculi function, CYP450 metabolism, and mitochondrial toxicity endpoints.

Nephrotoxicity

Proximal tubule injury, glomerular filtration changes, and drug-drug interactions affecting renal clearance.

Neurotoxicity

Blood-brain barrier penetration, neuronal viability, seizure liability, and CNS off-target effects assessment.

Pulmonary Toxicity

Alveolar epithelial damage, surfactant disruption, and inhaled drug toxicity in lung-on-chip models.

Genotoxicity

DNA damage assessment, mutagenicity screening, and chromosomal aberration detection using human primary cells.

Validated Toxicity Endpoints

Regulatory-accepted biomarkers for comprehensive safety profiling.

ALT/AST Elevation

Liver transaminase release indicating hepatocellular damage

hERG Channel Inhibition

Potassium channel block predicting QT prolongation risk

Mitochondrial Dysfunction

ATP depletion and oxidative stress markers

Bile Salt Export Pump (BSEP)

Cholestatic hepatotoxicity prediction

KIM-1 / NGAL

Early kidney injury biomarkers for nephrotoxicity

Troponin Release

Cardiac myocyte damage indicator

Industry Leaders

Companies pioneering organ-on-chip toxicology platforms.

Emulate Leader

Liver-Chip with 87% DILI sensitivity, FDA-qualified

$2.6B valuation

CN Bio Liver

PhysioMimix multi-organ toxicity platform

AstraZeneca partner

TissUse Multi-Organ

HUMIMIC multi-organ chips for systemic toxicity

4-organ systems

Hesperos Integrated

Human-on-a-chip with serum-free pumpless design

FDA collaboration

InSphero 3D Models

3D InSight liver microtissues for chronic toxicity

14-day+ studies

Mimetas HTS

OrganoPlate high-throughput toxicity screening

384-well format

Key Research

Liver-Chip enables predictive pharmacology in drug development

Emulate Inc. Nature Biotechnology 2022 | 87% DILI sensitivity

FDA Modernization Act 2.0: Ending mandatory animal testing

US Congress Public Law 2022 | Landmark legislation

Multi-organ chips predict systemic drug toxicity in humans

Wyss Institute Science Translational Medicine 2020

ICH S7B/E14 Q&A: Using in vitro data for cardiac safety

ICH Guidelines Regulatory 2022 | hERG + organ chips

Own the Toxicity Platform

ToxChip.com - the definitive domain for next-generation toxicology screening and drug safety assessment.

Inquire About This Domain

Predict Toxicity.Protect Patients.